Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 8/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411523 | 0.83 | SLC6A4 (0.67) | SLC6A4KCNH2SLC6A2SLC6A3NPC1 | |
| SCHEMBL6454014 | 0.82 | SLC6A4 (0.65) | SLC6A4KCNH2SLC6A2SLC6A3NPC1 | |
| SCHEMBL6439473 | 0.81 | SLC6A4 (0.53) | SLC6A4KCNH2BCHESLC6A2SLC6A3 | |
| SCHEMBL4634908 | 0.79 | SLC6A4 (0.69) | SLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL6413756 | 0.77 | HRH3 (0.49) | SLC6A4KCNH2BCHESLC6A2SLC6A3 | |
| SCHEMBL23699966 | 0.72 | ALDH1A1 (0.53) | KCNH2NPC1RAB9A | |
| SCHEMBL7761513 | 0.71 | HSD11B1 (0.54) | SLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL4111248 | 0.71 | SLC6A2 (0.65) | SLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL6419535 | 0.70 | MEN1 (0.51) | SLC6A4KCNH2 | |
| SCHEMBL5887756 | 0.70 | SLC6A2 (0.62) | SLC6A4KCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2004111003-A1 | AMIDE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | SLC6A4, HTR3C, HTR3A | SLC6A4 1/4885KCNH2 754/4885BCHE 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.